Erratum to "Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)" [Atherosclerosis 200 (2008) 135-140] (DOI:10.1016/j.atherosclerosis.2008.06.003);Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)

Atherosclerosis

Volumn 200, Issue 1, 2008, Pages 135-140

  Saito, Yasushi ^a   Yokoyama, Mitsuhiro ^b   Origasa, Hideki ^c   Matsuzaki, Masunori ^d   Matsuzawa, Yuji ^e   Ishikawa, Yuichi ^f   Oikawa, Shinichi ^g   Sasaki, Jun ^h   Hishida, Hitoshi ⁱ   Itakura, Hiroshige ^j   Kita, Toru ^k   Kitabatake, Akira ^l   Nakaya, Noriaki ^m   Sakata, Toshiie ⁿ   Shimada, Kazuyuki ^o   Shirato, Kunio ^p  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO PREFECTURAL AWAJI HOSPITAL   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e SUMITOMO HOSPITAL   (Japan)

^f KOBE UNIVERSITY   (Japan)

^g NIPPON MEDICAL SCHOOL   (Japan)

^h INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

ⁱ FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j IBARAKI CHRISTIAN UNIVERSITY   (Japan)

^k KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l Kano General Hospital   (Japan)

^m Nakaya Clinic   (Japan)

ⁿ NAKAMURA GAKUEN UNIVERSITY   (Japan)

^o JICHI MEDICAL UNIVERSITY   (Japan)

^p Saito Hospital   (Japan)

more..

Author keywords

Coronary artery disease; Eicosapentaenoic acid; HDL C; JELIS; Primary prevention; Risk factors; Triglycerides

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 49749128376     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.09.002     Document Type: Erratum

References (30)

1. Dyerberg J., Bang H.O., Stoffersen E., Moncada S., and Vane J.R. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?. Lancet 2 (1978) 117-119
2. Burr M.L., Fehily A.M., Gilbert J.F., et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 2 (1989) 757-761
3. Daviglus M.L., Stamler J., Orencia A.J., et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 336 (1997) 1046-1053
4. Hu F.B., Bronner L., Willett W.C., et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 287 (2002) 1815-1821
5. Iso H., Kobayashi M., Ishihara J., et al. Intake of fish and n-3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 113 (2006) 195-202
6. Morris M.C., Manson J.E., Rosner B., et al. Fish consumption and cardiovascular disease in the physicians' health study: a prospective study. Am J Epidemiol 142 (1995) 166-175
7. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-55.
8. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369 (2007) 1090-1098
9. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
10. Arai H., Yamamoto A., Matsuzawa Y., et al. Prevalence of metabolic syndrome in the general Japanese population in 2000. J Atheroscler Thromb 13 (2006) 202-208
11. DeFronzo R.A., and Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diab Care 14 (1991) 173-194
12. Kaplan N.M. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149 (1989) 1514-1520
13. Nakamura T., Tokunaga K., Shimomura I., et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107 (1994) 239-246
14. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
15. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
16. Ohnishi H., Saitoh S., Takagi S., et al. Incidence of insulin resistance in obese subjects in a rural Japanese population: the Tanno and Sobetsu Study. Diab Obes Metab 7 (2005) 83-87
17. Yokoyama M., and Origasa H. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J 146 (2003) 613-620
18. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
19. Shepherd J., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
20. Satoh N., Shimatsu A., Kotani K., et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diab Care 30 (2007) 144-146
21. Harris W.S., Park Y., and Isley W.L. Cardiovascular disease and long-chain omega-3 fatty acids. Curr Opin Lipidol 14 (2003) 9-14
22. Din J.N., Newby D.E., and Flapan A.D. Omega 3 fatty acids and cardiovascular disease-fishing for a natural treatment. BMJ 328 (2004) 30-35
23. Tamura Y., Hirai A., Terano T., et al. Clinical and epidemiological studies of eicosapentaenoic acid (EPA) in Japan. Prog Lipid Res 25 (1986) 461-466
24. Kawano H., Yano T., Mizuguchi K., Mochizuki H., and Saito Y. Changes in aspects such as the collagenous fiber density and foam cell size of atherosclerotic lesions composed of foam cells smooth muscle cells and fibrous components in rabbits caused by all-cis-5,8,11,14,17-icosapentaenoic acid. J Atheroscler Thromb 9 (2002) 170-177
25. Thies F., Garry J.M., Yaqoob P., et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 361 (2003) 477-485
26. Carmena R., Duriez P., and Fruchart J.C. Atherogenic lipoprotein particles in atherosclerosis. Circulation 109 (2004) III2-7
27. Ridker P.M. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 92 (2003) 17K-22K
28. Itoh M., Suganami T., Satoh N., et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 27 (2007) 1918-1925
29. Okamoto Y., Kihara S., Ouchi N., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (2002) 2767-2770
30. Fruebis J., Tsao T.S., Javorschi S., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98 (2001) 2005-2010